
In the second part of a two-part interview, Paz Vellanki of Precision for Medicine explains which confirmatory evidence can support a single-trial approval and why she expects FDA's rare disease framework to last.
Now supplying cleanroom doors, panels and accessories for all cleanroom applications.







